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group pts. Some of the pts wih G1 and G2 toxicities improved over 
time. 
Five yrs after the treatment the toxicities were as follows ( see table 
1). 
 
5year toxicities Low risk group 
(42 evaluable 
pts) 
Intermediate risk 
group (40 
evaluable pts) 
High risk group 
(8 evaluable pts) 
G0GU 30/42 (71.4%) 22/40 (55%) 6/8 (75%) 
G1GU 9/42 (21.4%) 13/40 (32.5%) 2/8 (25%) 
G2GU 3/42 (7.1%) 5/40 (12.5%) 0 
G0GI 35/42 (83.3%) 34/40 (85%) 7/8 (87.5%) 
G1GI 6/42 (14.3%) 3/40 (7.5%) 1/8 (12.5%) 
G2GI 1/42 (2.4%) 3/40 (7.5%) 0 
* ≥G3 toxicities were not registered at 5 year f-up 
 
Conclusions: This study shows very good results regarding the 5 year 
biochemical control: 100%, 97.5% and 75% in LR, IR and HR 
respectively. The G3 toxicity was manageable and has not persisted at 
5 yrs. Moderately hypofractionated HTT has proven to be a treatment 
that can achieve excellent results in terms of late bRFS and toxicity. 
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Purpose/Objective: The target volume for high risk group prostate 
cancer typically encompasses a large volume, the prostate, seminal 
vesicles (SV) and more often, the pelvic lymph nodes. Although IMRT 
and IGRT reduce the volume of irradiated OARs, the risk of toxicity 
still depends on the dose and irradiated volume. A phase II trial was 
devised in order to reduce the target volume, thereby including only 
the prostate for lymph node (LN) negative patients. Thus, the 
objective of the study was to evaluate the dosimetric and expected 
clinical benefit of this decreased target volume strategy. 
Materials and Methods: Patients with high risk prostate 
adenocarcinoma (D'Amico criteria), without SV involvement at MRI 
were included in the study. The patients underwent surgery to dissect 
large pelvic lymph node and SV. Two months after surgery, LN 
negative patients received 80Gy in the prostate only, by IMRT and 
IGRT (fiducials). LN positive patients had also a LN irradiation (46 Gy). 
Androgen deprivation was given after surgery for 3 years. 
The patients had a first planning CT performed before surgery (CT1) 
and a second one 2 months after surgery, before IMRT (CT2). 
A total of 4 plans were generated for each patient corresponding to 
different target volume configurations: 
- planning 1 (CT1):prostate + SV+ LN 
- planning 2 (CT2):prostate and LN 
- planning 3 (CT1):prostate and SV 
- planning 4 (CT2):prostate only 
The plans were compared using a Friedman test in terms of target 
volume, dose (including EUD) and NTCP. 
Results: The first 25 patients included in the trial between January 
2011 and July 2012 were analysed. The volume, dose and NTCP 
parameters are reported and compared in the Table. Thanks to 
surgery, the target volume was reduced by a factor 6 (planning 1 to 
planning 4). The mean doses in the rectum and the bladder were 
reduced by 30% and are even more dramatically decreased for the 
small bowel. The impact of this target volume reduction on the 
maximum dose in the OARs is however moderate, leading therefore to 
a slight reduction of the risk of toxicity. 
  
Conclusions: A significant reduction in target volumes in high-dose 
prostate irradiation dramatically reduces the average doses but not 
high doses in the OARs, leading to a moderate decrease in expected 
rectal and bladder toxicities.  
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Purpose/Objective: Estimation of various variants efficacy for proton 
boost fractionation at the proton-photon radiotherapy of the locally 
advanced prostate cancer. 
Materials and Methods: This investigation involves 272 patients with 
high and intermediate progression risk. 114 patients received 3D 
conformal local treatment of prostate with the use of a 220 MeV 
passively scattered proton beam and a special rectal marker – 
endostate under requirement of portal visualization.The proton RBE 
was taken as 1.1, and α/β used for prostate tumor was 3.0 Gy. The 
local dose 28.0 – 28.8 Gy (RBE) was delivered to prostate in 3 Gy (RBE) 
at 8 every day fractions (46 patients), or in 4 Gy (RBE) at 5 fractions - 
3 or 5fr/w (44 patients), or in 5.5 Gy (RBE) at 3 fractions - 3 fr/w (24 
patients). Taking into account the photon component (44Gy at 22 
fractions for the whole volume of the small pelvis), the dose for 
prostate amounted to 72.8, 72.0, and 72.0 Gy (RBE), respectively. 158 
patients in the control group received, additionally to the similar 
doses to the small pelvis, the local 4-field 68.0 – 72.0 Gy photon 
irradiation of the prostate in2Gy at 12 – 14 fractions. 
Results: An acute gastro-intestinal (GI) toxicity of the maximal grade 
2 intensity (RTOG/EORTC) was occurred reliably rarely after the 
proton – photon therapy: in 54.4% cases against 69.2% in the control 
group (p<0.01). Nograde 3 – 4 changes were registered. No differences 
in the rate and the stage of acute GU injuries after the proton-photon 
and photon therapy are observed.The rate of the grade 2 late injuries 
was 3 times less in the main group: 10.8%vs. 34.8% in the control 
group. The injuries of grade 3 – 4 are observed at one patient in the 
main group and at two patients in the control group. GU injuries are 
equally often observed after the proton-photon and the photon 
treatment: grade 2 - in 8.3% and 9.1%, and grade 3 – 4 -in 2.8% and 
3.8% of patients, respectively (p>0.05). The cummulative risk of grade 
3 – 4 GI the cummulative risk of grade 3 – 4 GU injuries was constant 
in range 1,5% of cases. No reliable differences in recurrence-free and 
overall survival after the proton-photon and the photon therapy were 
discovered. 5 year actuarial biochemical failure-free survival was 60.0 
± 5.4% and 61.9 ± 4.4% in the main and the control groups, and 9 year 
actuarial survival was 45.5 ± 8.5% and 42.8 ± 7.1%, respectively 
(p>0.05). On the whole, in 5 years 74.0 ± 5.0% of patients were alive 
after the proton-photon treatment and 78.8 ± 4.1% in the control 
group, and in 9 years – 55.9 ± 9.0% and 60.6 ± 5.7%, respectively 
(p>0.05). 
Conclusions: The precise local proton beam treatment with the 
fractional dose 3 – 5.5Gy (RBE) and with the total dose 28.0 – 28.8 Gy 
(RBE) as a boost to the photon treatment of the whole volume of 
pelvis reliably reduces the intensity of acute and late post-irradiation 
rectitis, but does not cut the risk of the low urinary tracts, and does 
not influence the anti-tumor efficacy of the treatment as compared to 
the traditional conformal photon radiation therapy. Besides, the 
proton boost regimens - 3 Gy (RBE) at 8 every day fractions, 4 Gy 
(RBE) at 5 fractions every other day, and 5.5 Gy (RBE) at 3 fractions 
every other day – do not differ reliably in the toxicity level values. 
   
 
 
